Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece

Rheumatology

Volumn 38, Issue SUPPL. 1, 1999, Pages 39-46

  Liaropoulos, L ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

AEs; Cost of AEs; Greece; Nimesulide; NSAIDs; Rheumatic disease

Indexed keywords

DICLOFENAC; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

CONFERENCE PAPER; CONTROLLED STUDY; GASTROINTESTINAL SYMPTOM; GREECE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; RHEUMATIC DISEASE;

AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; GASTROINTESTINAL DISEASES; GREECE; HOSPITALIZATION; HUMANS; INCIDENCE; RHEUMATIC DISEASES; SULFONAMIDES;

EID: 0032727573     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.suppl_1.39     Document Type: Conference Paper

References (32)

1. Henry D. Economic analysis as an aid to subsidization decisions: the development of Australia's guidelines for pharmaceuticals. PharmacoEconomics 1992;1:54-67.
2. Luce BR, Brown R. The use of technology assessment by hospitals, health maintenance organizations, and third party payers in the United States. Int J Technol Assess Health Care 1995;11:79-92.
3. Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ 1992;1:85-92.
4. Luce BR, Elixhauser A. Standards for socio-economic evaluations of health care products and services. Berlin: Springer-Verlag, 1990.
5. Bourgeois P, Dreiser RL, Lequesne MG et al. Multi-centre double-blind study to define the most favorable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheumatol Inflamm 1994;14:39-50.
6. Dreiser RL, Benevelli DC. Long-term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs 1993; 46(suppl. 1):270-4.
7. Quattrini M, Paladin S. A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthritis of the hip. Clin Drug Invest 1995;10:139-46.
8. Gold MR, Siegel JE, Russel LB et al. (eds) Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
9. Canadian Coordinating Office for Health Technology Assessment. Guidelines for the economic evaluation of pharmaceuticals. 1st edn, Canada. Ottawa: CCOHTA, 1994.
10. Storm BL. What is pharmacoepidemiology? Pharmacoepidemiology, 2nd edn. Philadelphia: Wiley, 1994.
11. Jansen RB, Burrell A, Nuitjen MJC et al. An economic evaluation of meloxicam 7.5 mg versus diclofenac 100 mg retard in the treatment of osteoarthritis in the UK: a decision analysis model based on gastrointestinal complications. Br J Med Econ 1996;10:247-62.
12. Bellamy N, Bensen WG, Beaulieu A et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 1995;22:915-20.
13. Fusetti G, Magni E, Armandola MC. Tolerability of nimesulide. Epidemiological data. Drugs 1993;46(suppl. 1): 227-80.
14. Lucker PW, Pawlowski C, Friederich I et al. Double-blind, randomised, multi-center clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994;14:29-38.
15. Milvio C, Borellini P, Milvio E. Tolerability of nimesulide. A long-term clinical trial. Arch Med Intern 1983;35:127-36.
16. Pochobradsky MG, Mele G, Beretta A et al. Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res 1991;17:197-204.
17. Porto A, Almeida H, Cunha MJ et al. Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients. Eur J Rheumatol Inflamm 1994;14:33-8.
18. Reiner M. Nimesulide in the short-term treatment of osteoarthrosis: a pilot study for assessing the minimal effective dose. J Int Med Res 1982;10:92-8.
19. Ventura R, Varriale E, Marinoni P. Studio clinico su un nuovo anti-infiammatorio non steroideo: la nimesulide. Ortoped Traumatol Oggi 1985;5:267-71.
20. Bakshi R, Darekar B, Langdom CG et al. Comparative efficacy and tolerability of two diclofenac formulations in the treatment of painful osteoarthritis. Br J Clin Pract 1996;50:294-7.
21. Ward DE, Veys EM, Bowdler JM et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995;14:656-62.
22. Bakshi R, Darekar B, Langdom CG et al. Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis. Curr Med Res Opin 1991;12:459-65.
23. Bellamy N, Buchanan WW, Chalmers A et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993;20:999-1004.
24. Eversmeyer W, Poland M, DeLapp RE et al. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993;95(suppl. 2A):10S-18S.
25. Grisanti AM, Lopes AA, Samara AM. Comparison of etodolac and diclofenac in osteoarthritis of the knee. Clin Ther 1992;14:791-800.
26. Kidd B, Frenzel W. A multicenter, randomized, double-blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996;23:1605-11.
27. Khan FM, Williams PI. Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee. Curr Med Res Opin 1992;13:1-12.
28. Rothman KJ. Modern epidemiology. Boston: Little, Brown & Co., 1986:29.
29. Turoff F. The policy Delphi. In: Linstone HA, Turoff M, eds. The Delphi method. Techniques and applications. Reading, MA: Addison-Wesley, 1975.
30. Smith BA. A report on the Greek Health Services. Athens: Ministry of Health, 1994.
31. Ministry of Health, Proceedings on the Committee on Hospital Costs, unpublished document, Athens, 1997.
32. Ahlbom A, Norell S. Introduction to modern epidemiology, 2nd edn. Chestnut Hill, Newton: Epidemiology Resources Inc., 1990.